Mark Schneider SRL
Mark Schneider reported total assets of 113,169 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026).
The score of Mark Schneider shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -50 % Total assets -47 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Mark Schneider's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 45,189 € | ||||
| Equity | 75,956 € | ||||
| Cash | 33,203 € | ||||
| EBITDA | 71,250 € | ||||
| Total assets | 113,169 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 06 Aug 2025
- Year ended 31 Dec 2023filed on 10 Jul 2024
- Year ended 31 Dec 2022filed on 12 May 2023
- Year ended 31 Dec 2021filed on 31 May 2022
Mark Schneider's financial analysis
- Solvency67.1%sector median: 32.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Mark Schneider
Mark Schneider's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0675.754.557
- VAT number
- BE0675754557
- Peppol
- Registered · 0208:0675754557 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 16 May 2017
- Registered office
- 1040 Etterbeek
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Mark Schneider (SRL) has been based in Etterbeek since 2017, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 45,189 € and equity of 75,956 €; its revenue is not published. Its solvency stands at 67.1%, above the median of its sector (32.3%).
Companies similar to Mark Schneider
Companies in the same business, of comparable size and area, outside its group.
- LES Laboratoires Repouss Wholesale of perfume and cosmetics Watermael-Boitsfort · balance sheet 89,745 €
- Cirba Wholesale of pharmaceutical and medical goods Ixelles · balance sheet 67,062 €
- Naqi Belgium Wholesale of perfume and cosmetics Brussels · balance sheet 409,764 €
- AlphaCare Wholesale of pharmaceutical and medical goods Grez-Doiceau · balance sheet 559,557 €
- Apogalenos Wholesale of perfume and cosmetics Anderlecht · balance sheet 70,103 €
- Accuray Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet 257,954 €
- Fortilab Manufacture of pharmaceutical preparations Etterbeek · balance sheet €1.39m
- Karys Group Wholesale of perfume and cosmetics Woluwe-Saint-Lambert · balance sheet 36,872 €
Frequently asked questions about Mark Schneider
What is the revenue of Mark Schneider?
Mark Schneider files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Mark Schneider?
In Belgium, the VAT number is the company number prefixed with BE: BE0675754557 for Mark Schneider, if the company is VAT-registered. Its company number (CBE) is 0675.754.557.
Where is the registered office of Mark Schneider?
According to the CBE register, the registered office of Mark Schneider is in 1040 Etterbeek.
What is the equity of Mark Schneider?
At the close of the 2025 financial year, the equity of Mark Schneider amounts to 75,956 €, a solvency of 67.1% of total assets.
Who manages Mark Schneider?
The register lists 1 active mandates at Mark Schneider. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Mark Schneider
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →